Published in Nat Med on March 02, 2008
A20: central gatekeeper in inflammation and immunity. J Biol Chem (2008) 2.83
A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol (2012) 2.47
Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev (2008) 2.29
Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01
Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00
Regulation of NF-κB by deubiquitinases. Immunol Rev (2012) 1.78
Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol (2011) 1.77
Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity (2011) 1.63
Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest (2011) 1.54
Molecular mechanisms of treg-mediated T cell suppression. Front Immunol (2012) 1.41
Regulation of NF-κB signaling by the A20 deubiquitinase. Cell Mol Immunol (2012) 1.33
Beyond empiricism: informing vaccine development through innate immunity research. Cell (2012) 1.31
Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) (2010) 1.29
Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio (2010) 1.22
Neurodegenerative and inflammatory pathway components linked to TNF-α/TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci (2011) 1.17
Expression of tumor necrosis factor alpha-induced protein 3 mRNA in peripheral blood mononuclear cells negatively correlates with disease severity in psoriasis vulgaris. Clin Vaccine Immunol (2012) 1.15
A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol (2009) 1.12
Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther (2011) 1.10
Twist-2 controls myeloid lineage development and function. PLoS Biol (2008) 1.10
Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One (2013) 1.06
Usp12 stabilizes the T-cell receptor complex at the cell surface during signaling. Proc Natl Acad Sci U S A (2016) 1.03
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets (2009) 1.01
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol (2010) 0.97
Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity. Cancer Res (2011) 0.96
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol (2011) 0.95
Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells (2009) 0.94
A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol (2011) 0.94
A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-κB signaling. PLoS One (2012) 0.94
A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther (2010) 0.92
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer (2014) 0.92
Dendritic cell-based vaccines: barriers and opportunities. Future Oncol (2012) 0.91
Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML. Cancer Cell Int (2013) 0.90
Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population. J Biomed Biotechnol (2010) 0.88
The role of A20 in the pathogenesis of lymphocytic malignancy. Cancer Cell Int (2012) 0.87
Mapping quantitative trait loci for T lymphocyte subpopulations in peripheral blood in swine. BMC Genet (2011) 0.87
Enhancement of dendritic cells as vaccines for cancer. Immunotherapy (2010) 0.86
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1. Blood (2014) 0.85
Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther (2009) 0.83
Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Immunology (2014) 0.83
Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology (2012) 0.83
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol (2013) 0.83
In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small (2014) 0.83
Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2011) 0.81
A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren's syndrome. Histochem Cell Biol (2011) 0.81
A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity. PLoS One (2012) 0.80
Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev (2011) 0.80
Epigenetic Regulation of Antibody Responses by the Histone H2A Deubiquitinase MYSM1. Sci Rep (2015) 0.79
A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine (2012) 0.79
A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One (2013) 0.79
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol (2012) 0.78
Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J Leukoc Biol (2016) 0.78
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One (2012) 0.78
The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep (2011) 0.78
Adoptive cell therapy for sarcoma. Immunotherapy (2015) 0.78
Altered expression of A20 gene in peripheral blood mononuclear cells is associated with the progression of chronic hepatitis B virus infection. Oncotarget (2016) 0.78
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun (2014) 0.77
Increased A20 mRNA Level in Peripheral Blood Mononuclear Cells is Associated With Immune Phases of Patients With Chronic Hepatitis B. Medicine (Baltimore) (2015) 0.77
In Vivo Silencing of A20 via TLR9-Mediated Targeted SiRNA Delivery Potentiates Antitumor Immune Response. PLoS One (2015) 0.77
Inhibitory RNA molecules in immunotherapy for cancer. Methods Mol Biol (2010) 0.77
Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs. Gene Ther (2011) 0.76
Mysm1 is required for interferon regulatory factor expression in maintaining HSC quiescence and thymocyte development. Cell Death Dis (2016) 0.76
Inhibition of A20 expression in tumor microenvironment exerts anti-tumor effect through inducing myeloid-derived suppressor cells apoptosis. Sci Rep (2015) 0.76
An effective vaccination approach augments anti-HIV systemic and vaginal immunity in mice with decreased HIV-1 susceptible α4β7high CD4+ T cells. Curr HIV Res (2013) 0.75
A20 plays a critical role in the immunoregulatory function of mesenchymal stem cells. J Cell Mol Med (2016) 0.75
Solving the genetic puzzle of systemic lupus erythematosus. Pediatr Nephrol (2014) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science (2000) 10.98
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol (2004) 9.42
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol (2000) 9.15
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med (2007) 7.73
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol (2005) 6.77
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol (2004) 4.62
Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med (2003) 4.41
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol (2004) 3.15
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem (1995) 2.05
Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol (2007) 1.82
Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol (2004) 1.78
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol (2004) 1.71
A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol (2005) 1.63
Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol (2006) 1.36
Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J Immunol (2005) 1.32
Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol (2005) 1.31
Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol (2005) 1.20
Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol (2003) 0.93
Lentiviral transduction of human dendritic cells. Methods Mol Biol (2004) 0.89
Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol Ther (2006) 0.82
Phorbol myristate acetate induces both high affinity and low affinity interleukin 2-receptors on a pre-B leukemic cell line. Leuk Res (1990) 0.78
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res (2008) 8.01
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med (2011) 5.16
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 2.56
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Isoform discovery by targeted cloning, 'deep-well' pooling and parallel sequencing. Nat Methods (2008) 2.03
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res (2012) 1.77
Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res (2004) 1.76
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol (2010) 1.63
Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity (2011) 1.63
Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA (2007) 1.60
The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood (2011) 1.57
Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest (2011) 1.54
CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther (2005) 1.51
Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther (2006) 1.44
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst (2004) 1.42
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther (2011) 1.32
Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther (2004) 1.32
Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet (2006) 1.31
Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One (2011) 1.27
Light whole genome sequence for SNP discovery across domestic cat breeds. BMC Genomics (2010) 1.27
Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA (2007) 1.24
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res (2002) 1.23
Pulmonary benign metastasizing leiomyoma from uterine leiomyoma. World J Surg Oncol (2013) 1.22
HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology (2011) 1.22
The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res (2012) 1.21
Human T lymphotropic virus type-1 p30II alters cellular gene expression to selectively enhance signaling pathways that activate T lymphocytes. Retrovirology (2004) 1.17
Complete genome sequence of the probiotic Lactobacillus plantarum strain ZJ316. Genome Announc (2013) 1.17
Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol (2012) 1.17
Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun (2005) 1.16
An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med (2006) 1.15
ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One (2013) 1.14
Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab (2005) 1.14
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer (2012) 1.12
Intramedullary fixation of subtrochanteric fractures with long proximal femoral nail or long gamma nail: technical notes and preliminary results. Ann Acad Med Singapore (2007) 1.12
Heteropolyanion-based ionic liquids: reaction-induced self-separation catalysts for esterification. Angew Chem Int Ed Engl (2009) 1.12
Twist-2 controls myeloid lineage development and function. PLoS Biol (2008) 1.10
Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol (2010) 1.10
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol (2014) 1.08
A Bayesian approach to subgroup identification. J Biopharm Stat (2014) 1.08
Recurrent lumbar disc herniation after discectomy: outcome of repeat discectomy. Surg Neurol (2005) 1.08
Predicting gene expression from sequence: a reexamination. PLoS Comput Biol (2007) 1.08
Differential neuronal and glial expression of GluR1 AMPA receptor subunit and the scaffolding proteins SAP97 and 4.1N during rat cerebellar development. J Comp Neurol (2007) 1.07
The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. PLoS One (2011) 1.07
Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res (2002) 1.05
CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther (2010) 1.05
1,5-Dimethyl-2-nitro-imino-1,3,5-tri-azinane. Acta Crystallogr Sect E Struct Rep Online (2008) 1.05
Combining phylogenetic motif discovery and motif clustering to predict co-regulated genes. Bioinformatics (2005) 1.04
Lanthanide-containing polymer nanoparticles for biological tagging applications: nonspecific endocytosis and cell adhesion. J Am Chem Soc (2007) 1.03
Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther (2004) 1.03
The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. Am J Respir Cell Mol Biol (2007) 1.03
Predictive factors of lymph node status in small peripheral non-small cell lung cancers: tumor histology is more reliable. Ann Surg Oncol (2012) 1.01
Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Hum Genet (2006) 1.00
The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. Blood (2013) 0.99
A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res (2003) 0.98
Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res (2004) 0.98
The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun (2012) 0.98
Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother (2009) 0.97
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol (2010) 0.97
B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci (2013) 0.96
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 0.95
The effect of heme oxygenase-1 complexed with collagen on MSC performance in the treatment of diabetic ischemic ulcer. Biomaterials (2012) 0.95
A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol (2014) 0.95
Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res (2003) 0.95
Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res (2003) 0.95
Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells (2009) 0.94
Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology (2007) 0.94
Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother (2013) 0.94
Smad3 mediates TGF-beta1-induced collagen gel contraction by human lung fibroblasts. Biochem Biophys Res Commun (2005) 0.93
A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther (2010) 0.92